Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis

References

• Pelechas E, Kaltsonoudis E, Voulgari PV, et al. Rheumatoid Arthritis. In: Eleftherios Pelechas, editor. Illustrated handbook of rheumatic and musculo-skeletal diseases. Cham: Springer; 2019. p. 45–76.
   Google Scholar
• Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4(3):130–136.
   PubMed Web of Science ®Google Scholar
• Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American college of rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36(3):182–188.
   PubMed Web of Science ®Google Scholar
• Drosos AA, Alamanos I, Voulgari PV, et al. Epidemiology of adult rheumatoid arthritis in northwest Greece 1987-1995. J Rheumatol. 1997;24(11):2129–2133.
   PubMed Web of Science ®Google Scholar
• Krause ML, Crowson CS, Bongartz T, et al. Determinants of disability in rheumatoid arthritis: a community-based cohort study. Open Rheumatol J. 2015;9(1):88–93.
   PubMedGoogle Scholar
• Papadopoulos CG, Gartzonikas IK, Pappa TK, et al. Eight-year survival study of first-line tumour necrosis factor α inhibitors in rheumatoid arthritis: a real-world data from a university centre registry. Rheumatol Adv Pract. 2019;3(1):rkz007.
   PubMedGoogle Scholar
• Pelechas E, Voulgari PV, Drosos AA. Golimumab for rheumatoid arthritis. J Clin Med. 2019;8(3):pii:E387. 20.
   Web of Science ®Google Scholar
• Pelechas E, Drosos AA. Etanercept biosimilar SB-4. Expert Opin Biol Ther. 2019;19(3):173–179.
   PubMed Web of Science ®Google Scholar
• Pelechas E, Voulgari PV, Drosos AA. ABP 501 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2018;18(3):317–322.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Keystone E, Genovese MC, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis. 2010;69(6):1158–1161.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Cohen SB, Emery P, et al. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol. 2012;39(12):2238–2246.
   PubMed Web of Science ®Google Scholar
• Finckh a, Moller B, Dudler J, et al. Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists. Ann Rheum Dis. 2012;71(10):1680–1685.
   PubMed Web of Science ®Google Scholar
• Pavelka K, Gatterova J, Tegzova D, et al. Radiographic progression of rheumatoid arthritis in patients from the Czech National registry receiving infliximab treatment. Clin Exp Rheumatol. 2007;25(4):540–545.
   PubMed Web of Science ®Google Scholar
• Van der Heijde D, Klareskog L, Landewe R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(12):3928–3939.
   PubMed Web of Science ®Google Scholar
• Emery P, Genovese MC, van Vollenhoven R, et al. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol. 2009;36(7):1429–1441.
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, van der Heijde D, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum. 2011;63(5):1200–1210.
   PubMedGoogle Scholar
• Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. a randomised controlled trial. Ann Rheum Dis. 2009;68(6):797–804.
   PubMed Web of Science ®Google Scholar
• Paget SA. Efficacy of anakinra in bone: comparison to other biologics. Adv Ther. 2002;19(1):27–39.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63(3):609–621.
   PubMed Web of Science ®Google Scholar
• Drosos AA, Tsifetaki N, Tsiakou EK, et al. Influence of methotrexate on radiographic progression in rheumatoid arthritis: a sixty-month prospective study. Clin Exp Rheumatol. 1997;15(3):263–267.
   PubMed Web of Science ®Google Scholar
• Van der Hijde DM, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and Sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;1(8646):1036–1038.
   PubMed Web of Science ®Google Scholar
• Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide rheumatoid arthritis investigators group. Arthritis Rheum. 2000;43(3):495–505.
   PubMed Web of Science ®Google Scholar
• Strand V, Kavanaugh a, Kivitz AJ, et al. Long-term radiographic and patient-reported outcomes in patients with rheumatoid arthritis treated with tofacitinib: ORAL start and ORAL scan post-hoc analyses. Rheumatol Ther. 2018;5(2):341–353.
   PubMed Web of Science ®Google Scholar
• Drosos AA, Voulgari PV, Papadopoulos IA, et al. Cyclosporine a in the treatment of early rheumatoid arthritis. a prospective, randomized 24-month study. Clin Exp Rheumatol. 1998;16(6):695–701.
   PubMed Web of Science ®Google Scholar
• Marchesoni a, Battafarano N, Arreghini M, et al. Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology (Oxford). 2003;42(12):1545–1549.
   PubMed Web of Science ®Google Scholar
• Drosos AA, Pelechas E, Voulgari PV. Conventional radiography of the hands and wrists in rheumatoid arthritis. What a rheumatologist should know and how to interpret the radiological findings. Rheumatol Int. 2019;39(8):1331–1341.
   PubMed Web of Science ®Google Scholar
• Kaltsonoudis E, Pelechas E, Voulgari PV, et al. Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. Semin Arthritis Rheum. 2019;48(4):597–602.
   PubMed Web of Science ®Google Scholar
• Park S, Le TT, Slejko JF, et al. Changes in opioid utilization following tumor necrosis factor inhibitor initiation in patients with rheumatoid arthritis. Rheumatol Ther. 2019;6(4):611–616.
   PubMed Web of Science ®Google Scholar
• Ho KY, Gwee KA, Cheng YK, et al. Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice. J Pain Res. 2018;11:1937–1948.
   PubMed Web of Science ®Google Scholar
• Zamora-Legoff JA, Achenbach SJ, Crowson CS, et al. Opioid use in patients with rheumatoid arthritis 2005-2014: a population-based comparative study. Clin Rheumatol. 2016;35(5):1137–1144.
   PubMed Web of Science ®Google Scholar
• Carr DB, Goudas LC. Acute pain. Lancet. 1999;353(9169):2051–2058.
   PubMed Web of Science ®Google Scholar
• Wu CL, Raja SN. Treatment of acute postoperative pain. Lancet. 2011;377(9784):2215–2225.
   PubMed Web of Science ®Google Scholar
• Hanks GW, de Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84(5):587–593.
   PubMed Web of Science ®Google Scholar
• Money S, Garber B. Management of cancer pain. Curr Emerg Hosp Med Rep. 2018;6(4):141–146.
   Web of Science ®Google Scholar
• Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372–380.
   PubMed Web of Science ®Google Scholar
• Eriksen J, Sjogren P, Bruera E, et al. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain. 2006;125(2):172–179.
   PubMed Web of Science ®Google Scholar
• Von Korff M, Saunders K, Ray GT, et al. Defacto long-term opioid therapy for non-cancer pain. Clin J Pain. 2008;24(6):521–527.
   PubMed Web of Science ®Google Scholar
• Busse JW, Craigie S, Juurlind DN, et al. Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017;189(18): E659–E666.
   PubMed Web of Science ®Google Scholar
• Noble M, Tregear SJ, Treadwell JR, et al. Long-term Opioid Therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage. 2008;35(2):214–228.
   PubMed Web of Science ®Google Scholar
• Hauser W, Bernardy K, Maier C. Long-term opioid therapy in chronic noncancer pain. a systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks. Schmerz. 2015;29(1):96–108.
   PubMed Web of Science ®Google Scholar
• Vowles KE, McEntee ML, Julnes PS, et al. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569–576.
   PubMed Web of Science ®Google Scholar
• Stoeber M, Jullie D, Lobingier BT, et al. a genetically encoded biosensor reveals location bias of opioid drug action. Neuron. 2018;98(5):963–976.
   PubMed Web of Science ®Google Scholar
• Cox BM, Christie MJ, Devi L, et al. Challenges for opioid receptor nomenclature: IUPHAR Review 9. Br J Pharmacol. 2015;172(2):317–323.
   PubMed Web of Science ®Google Scholar
• Bruehl S, Burns JW, Gupta R, et al. Endogenous opioid function mediates the association between laboratory evoked pain sensitivity and morphine analgesic responses. Pain. 2013;154(9):1856–1864.
   PubMed Web of Science ®Google Scholar
• Basso L, Boue J, Mahiddine K, et al. Endogenous analgesia mediated by CD4</sup>+ T lymphocytes is dependent on enkephalins in mice. J Neuroinflammation. 2016;13(1):132.
   PubMedGoogle Scholar
• Liang X, Liu R, Chen C, et al. Opioid system modulates the immune function: a review. Transl Perioper Pain Med. 2016;1(1):5–13.
   Google Scholar
• Ahlbeck K. Opioids: a two-faced Janus. Curr Med Res Opin. 2011;27(2):439–448.
   PubMed Web of Science ®Google Scholar
• Pathan H, Williams J. Basic opioid pharmacology: an update. Br J Pain. 2012;6(1):11–16.
   PubMedGoogle Scholar
• Whittle SL, Richards BL, van der Heijde DM, et al. The efficacy and safety of opioids in inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl. 2012;90:40–46.
   PubMedGoogle Scholar
• Whittle SL, Richards BL, Buchbinder R. Opioid analgesics for rheumatoid arthritis pain. JAMA. 2013;309(5):485–486.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Radner H, van der Heijde DM, et al. Combination therapy for pain management in inflammatory arthritis: a cochrane systematic review. J Rheumatol Suppl. 2012;90:47–55.
   PubMedGoogle Scholar
• Heiberg T, Kvien TK. Preferences for improved health examined in 1024 patients with rheumatoid arthritis: pain has highest priority. Arthritis Rheum. 2002;47(4):391–397.
   PubMedGoogle Scholar
• Dutta R, Lunzer MM, Auger JL, et al. A bivalent compound targeting CCR5 and the mu opioid receptor treats inflammatory arthritis pain in mice without inducing pharmacologic tolerance. Arthritis Res Ther. 2018;20(1):154.
   PubMedGoogle Scholar
• Minnock P, FitzGerald O, Bresnihan B. Women with established rheumatoid arthritis perceive pain as the predominant impairment of health status. Rheumatology. 2003;42(8):995–1000.
   PubMed Web of Science ®Google Scholar
• Parsadaniantz SM, Rivat C, Rostene W, et al. Opioid and chemokine receptor crosstalk. a promising target for pain therapy? Nat Rev Neurosci. 2015;16(2):69–78.
   PubMed Web of Science ®Google Scholar
• Koch AE. Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum. 2005;52(3):710–721.
   PubMed Web of Science ®Google Scholar
• Akgun E, Javed MI, Lunzer MM, et al. Inhibition of inflammatory and neuropathic pain by targeting a mu opioid receptor/chemokine receptor5 heteromer (MOR-CCR5). J Med Chem. 2015;58(21):8647–8657.
   PubMed Web of Science ®Google Scholar
• Hua S, Wu SY. The use of lipid-based nanocarriers for targeted pain therapies. Front Pharmacol. 2013;4:143.
   PubMed Web of Science ®Google Scholar
• Hua S, Dias TH, Pepperall DG, et al. Topical loperamide-encapsulated liposomal gel increases the severity of inflammation and accelerates diseases progression in the adjuvant-induced model of experimental rheumatoid arthritis. Front Pharmacol. 2017;8:503.
   PubMed Web of Science ®Google Scholar
• Spahn V, Del Vecchio G, Labuz D, et al. a nontoxic pain killer designed by modelling of pathological receptor conformations. Science. 2017;355(6328):966–969.
   PubMed Web of Science ®Google Scholar
• Rodriguez=Gaztelumendi a, Spahn V, Labuz D, et al. Analgesic effects of a novel pH-dependent μ-opioid receptor agonist in models of neuropathic and abdominal pain. Pain. 2018;159(11):2277–2284.
   PubMed Web of Science ®Google Scholar
• Spahn V, Del Vecchio G, Rodriguez-Gaztelumendi a, et al. Opioid receptor signalling, analgesic and side effects induced by a computationally designed pH-dependent agonist. Sci Rep. 2018;8(1):8965.
   PubMedGoogle Scholar
• DeWire SM, Yamashita DS, Rominger DH, et al. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013;344(3):708–717.
   PubMed Web of Science ®Google Scholar
• Machelska H, Celik MO. Advances in achieving opioid analgesia without side effects. Front Pharmacol. 2018;9: 1388.
   Google Scholar
• Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem. 2003;72(1):291–336.
   PubMedGoogle Scholar
• Lu Z, Xu J, Xu M, et al. Truncated μ-opioid receptors with 6 transmembrane domains are essential for opioid analgesia. Anesth Analg. 2018;126(3):1050–1057.
   PubMed Web of Science ®Google Scholar
• Lee YC, Kremer J, Guan H, et al. Chronic opioid use in rheumatoid arthritis: prevalence and predictors. Arthritis Rheumatol. 2019;71(5):670–677.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xie F, Smith C, et al. Changing trends in opioid use among patients with rheumatoid arthritis in the United States. Arthritis Rheumatol. 2017;69(9): 1733–1740.
   PubMed Web of Science ®Google Scholar
• Weisberg DF, Becker WC, Fiellin DA, et al. Prescription opioid misuse in the United States and the United Kingdom: cautionary lessons. Int J Drug Policy. 2014;25(6):1124–1130.
   PubMed Web of Science ®Google Scholar
• Van Amsterdam J, van den Brink W, Van Den Brink W. The misuse of prescription opioids: a threat for Europe? Curr Drug Abuse Rev. 2015;8(1):3–14.
   PubMedGoogle Scholar
• Nelson LS, Perrone J. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS). JAMA. 2012;308(5):457–458.
   PubMed Web of Science ®Google Scholar
• Australian Institute of Health and Welfare. Opioid harm in Australia and comparisons between Australia and Canada. Accessed on 2020 Feb 06, Available at: www.aihw.gov.au/getmedia/605a6cf8-6e53-488e-ac6e-925e9086df33/aihw-hse-210.pdf.aspx?inline=true.
   Google Scholar
• U.S. Department of Health and Human Services. The U.S. opioid epidemic. accessed on 2020 Feb 06www.hhs.gov/opioids/about-the-epidemic/index.html
   Google Scholar
• Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Therapy. 2005;7(5):R1046–R1051.
   PubMed Web of Science ®Google Scholar
• Farrell M. Opiate withdrawal. Addiction. 1994;89(11):1471–1475.
   PubMed Web of Science ®Google Scholar
• Dumas EO, Pollack GM. Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective. Aaps J. 2008;10(4):537–551.
   PubMed Web of Science ®Google Scholar
• Lee M, Silverman SM, Hansen H, et al. a comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145–161.
   PubMed Web of Science ®Google Scholar
• Weissman DE, Haddox JD. Opioid pseudoaddiction – an iatrogenic syndrome. Pain. 1989;36(3):363–366.
   PubMed Web of Science ®Google Scholar
• Edlund MJ, Steffick D, Hudson T, et al. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain. 2007;129(3):355–362.
   PubMed Web of Science ®Google Scholar
• Porreca F, Ossipov MH. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options. Pain Med. 2009;10(4):654–662.
   PubMed Web of Science ®Google Scholar
• Andresen V, Layer P. Medical therapy of constipation: current standards and beyond. Visc Med. 2018;34(2):123–127.
   PubMed Web of Science ®Google Scholar
• Sridharan K, Sivaramakrishnan G. Drugs for treating opioid-induced constipation: a mixed treatment comparison network meta-analysis of randomized controlled clinical trials. J Pain Symptom Manage. 2018;55(2):468–479.
   PubMed Web of Science ®Google Scholar
• Corbett K, Dugan a, Vitale C, et al. Long-term effects of opioids on the cardiovascular system: examine the evidence. Nursing. 2019;49(4):47–49.
   PubMedGoogle Scholar
• Correa D, Farney RJ, Chung F, et al. Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations. Anesth Analg. 2015;120(6):1273–1285.
   PubMed Web of Science ®Google Scholar
• Farmer AD, Ferdinand E, Aziz Q. Opioids and the gastrointestinal tract – a case of narcotic bowel syndrome and literature review. J Neurogastroenterol Motil. 2013;19(1):94–98.
   PubMed Web of Science ®Google Scholar
• Bigliardi PL, Tobin DJ, Gaveriaux-Ruff C, et al. Opioids and the skin – where do we stand? Exp Dermatol. 2009;18(5):424–430.
   PubMed Web of Science ®Google Scholar
• Gomes T, Mamdani MM, Dhalla IA, et al. Opioid dose and drug-related mortality in patients with non-malignant pain. Arch Intern Med. 2011;171(7):686–691.
   PubMed Web of Science ®Google Scholar
• Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351(27):2827–2831.
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Olter Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331–1346.
   PubMed Web of Science ®Google Scholar
• Corbett AD, Henderson G, McKnight AT, et al. 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol. 2006 Jan;147(Suppl1):S153–62.
   PubMedGoogle Scholar
• Drosos AA, Pelechas E, Voulgari PV. Rheumatoid arthritis treatment. a back to the drawing board project or high expectations for low unmet needs? J Clin Med. 2019;8(8):pii:E1237.
   Web of Science ®Google Scholar
• Stein C, Baerwald C. Opioids for the treatment of arthritis pain. Expert Opin Pharmacother. 2014;15(2):193–202.
   PubMed Web of Science ®Google Scholar
• Smith SR, Deshpande BR, Collins JE, et al. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage. 2016;24(6):962–972.
   PubMed Web of Science ®Google Scholar
• Fuggle N, Curtis E, Shaw S, et al. Safety of opioids in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(Suppl 1):129–143.
   PubMedGoogle Scholar
• Seth P, Rudd RA, Noonan RK, et al. Quantifying the epidemic of prescription opioid overdose deaths. Am J Public Health. 2018;108(4):500–502.
   PubMed Web of Science ®Google Scholar
• PDQ supportive and palliative care editorial board. Pain (PDQ): health professional version. 2015 Jul 16. In: PDQ Cancer information summaries. Nethesda (MD): National cancer institute (US); 2002-. https//www.ncbi.nlm.nih.gov/books/NBK65949.1
   Google Scholar